Enzo Biochem EBITDA Margin 2006-2021 | ENZ

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Enzo Biochem (ENZ) over the last 10 years. The current EBITDA margin for Enzo Biochem as of October 31, 2021 is .
Enzo Biochem EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2021-10-31 $0.12B $0.00B 0.86%
2021-07-31 $0.12B $0.00B 2.54%
2021-04-30 $0.11B $0.00B 1.77%
2021-01-31 $0.10B $-0.01B -10.31%
2020-10-31 $0.09B $-0.02B -22.35%
2020-07-31 $0.08B $-0.03B -35.53%
2020-04-30 $0.08B $-0.03B -36.36%
2020-01-31 $0.08B $0.00B 5.00%
2019-10-31 $0.08B $0.00B 3.75%
2019-07-31 $0.08B $0.00B 6.17%
2019-04-30 $0.08B $0.00B 6.02%
2019-01-31 $0.09B $-0.02B -22.73%
2018-10-31 $0.10B $-0.01B -14.74%
2018-07-31 $0.10B $-0.01B -8.91%
2018-04-30 $0.10B $-0.00B -3.88%
2018-01-31 $0.11B $-0.00B -0.95%
2017-10-31 $0.11B $0.00B 0.95%
2017-07-31 $0.10B $0.00B 0.96%
2017-04-30 $0.11B $0.04B 36.79%
2017-01-31 $0.11B $0.04B 34.29%
2016-10-31 $0.10B $0.04B 42.31%
2016-07-31 $0.10B $0.05B 48.54%
2016-04-30 $0.10B $0.02B 21.57%
2016-01-31 $0.10B $0.02B 22.00%
2015-10-31 $0.10B $0.01B 11.22%
2015-07-31 $0.10B $0.00B 3.06%
2015-04-30 $0.10B $-0.01B -9.28%
2015-01-31 $0.10B $-0.01B -7.22%
2014-10-31 $0.10B $-0.01B -7.22%
2014-07-31 $0.10B $-0.01B -7.29%
2014-04-30 $0.09B $-0.01B -7.45%
2014-01-31 $0.09B $-0.01B -11.83%
2013-10-31 $0.09B $-0.01B -14.13%
2013-07-31 $0.09B $-0.01B -14.89%
2013-04-30 $0.10B $-0.04B -41.24%
2013-01-31 $0.10B $-0.04B -38.00%
2012-10-31 $0.10B $-0.04B -34.95%
2012-07-31 $0.10B $-0.04B -34.95%
2012-04-30 $0.10B $-0.01B -10.58%
2012-01-31 $0.10B $-0.01B -9.62%
2011-10-31 $0.10B $-0.01B -10.68%
2011-07-31 $0.10B $-0.01B -7.77%
2011-04-30 $0.10B $-0.01B -9.90%
2011-01-31 $0.10B $-0.01B -12.12%
2010-10-31 $0.10B $-0.02B -17.35%
2010-07-31 $0.10B $-0.02B -18.56%
2010-04-30 $0.10B $-0.02B -17.53%
2010-01-31 $0.10B $-0.02B -17.71%
2009-10-31 $0.09B $-0.02B -15.96%
2009-07-31 $0.09B $-0.02B -21.11%
2009-04-30 $0.09B $-0.02B -20.93%
2009-01-31 $0.08B $-0.02B -20.73%
2008-10-31 $0.08B $-0.02B -18.99%
2008-07-31 $0.08B $-0.01B -15.58%
2008-04-30 $0.07B $-0.01B -18.92%
2008-01-31 $0.07B $-0.02B -24.64%
2007-10-31 $0.06B $-0.02B -29.03%
2007-07-31 $0.05B $-0.02B -37.74%
2007-04-30 $0.05B $-0.02B -46.67%
2007-01-31 $0.04B $-0.02B -48.78%
2006-10-31 $0.04B $-0.02B -47.50%
2006-07-31 $0.04B $-0.02B -47.50%
2006-04-30 $0.04B $-0.03B -73.17%
2006-01-31 $0.04B $-0.03B -66.67%
2005-10-31 $0.04B $-0.02B -55.81%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.154B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00